| External factors: | Lidamycin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Colorectal cancer |
| Experiment: | SA-β-gal activity assay |
| Description: | Significant induction of senescent phenotype was observed time dependently after 0.5 nM LDM treatment for 48 120 h, with the ratio of senescent cells reaching over 60% in both cells on day 5. Lower dose (0.25 nM) LDM also caused significant senescence. |
| Target gene: | EZH2 |
| R-EF-Target gene: | Downregulation |
| Official symbol(s): | EZH2 |
| Target gene experiment: | Western blot//RT-PCR |
| Target gene description: | Similar reductions of EZH2, EED and SUZ12 protein levels were observed by LDM treatment at various doses for 72 h .Further RT-PCR analysis confirmed significant reduction of EZH2 mRNA upon LDM treatment time dependently. |
| Regulatory pathway: | p21 |
| R-EF-Pathway: | Upregulation |
| Official symbol(s): | CDKN1A |
| Pathway experiment: | Western blot |
| Pathway description: | Consistent with our previous work,12 p53 is found to be increased after LDM treatment for 48 120 h in HCT116 cells harboring wild-type p53. Meanwhile, p53 downstream target p21 was increased. Although little changes of p53 expression were seen in SW620 cells carrying mutant p53, p21 level remained to be enhanced. The same tendency was also found dose dependently. |
Annotation: